Cargando…
Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have recently been reported in many countries. These have exacerbated the coronavirus disease 2019 (COVID-19)-induced global health threats and hindered COVID-19 vaccine development and therapeutic progress. This commentar...
Autores principales: | Hossain, Md. Jamal, Rabaan, Ali A., Mutair, Abbas Al, Alhumaid, Saad, Emran, Talha Bin, Saikumar, G, Mitra, Saikat, Dhama, Kuldeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862164/ https://www.ncbi.nlm.nih.gov/pubmed/35172687 http://dx.doi.org/10.1080/21645515.2022.2027197 |
Ejemplares similares
-
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
por: Dhama, Kuldeep, et al.
Publicado: (2022) -
Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders – Advances and challenges
por: Goswami, Tapas Kumar, et al.
Publicado: (2022) -
Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies
por: Sharun, Khan, et al.
Publicado: (2021) -
Viral Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in COVID-19
por: Rabaan, Ali A., et al.
Publicado: (2021) -
Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory
por: Bindu, Suresh, et al.
Publicado: (2022)